Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) / Roche, Halozyme  >>  Phase 2
Welcome,         Profile    Billing    Logout  

21 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) / Roche
2020-004414-35: Improving public cancer care by implementing precision medicine in Norway

Not yet recruiting
2
2000
Europe
Alpelisib, Fulvestrant, imatinib, Hydroxyurea, bortezomib, capmatinib, Dactinomycin, tepotinib, dostarlimab, Capsule, hard, Injection, Infusion, Tablet, Capsule, Solution for injection, Powder and solvent for suspension for injection, Powder for solution for injection, Concentrate for solution for infusion, Alecensa, Erivedge, Phesgo, Rozlytrek, Tecentriq, Avastin, Zelboraf, Cotellic, Mekinist, Tafinlar, Alkeran, Piqray, Lynparza, Pemazyre, Tabrecta, Retsevmo, Tepmetko, Gavreto, Zejula
Oslo University Hospital, Oslo University Hospital
Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible., Patients with a biomarker indicating response to the study drug can be included in the trial. Patients with disease characteristics covered in present indications for the study drug are not eligible., Diseases [C] - Cancer [C04]
 
 
2020-002918-41: De-Escalation of neoadjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade

Not yet recruiting
2
1065
Europe
FDC pertuzumab and trastuzumab with recombinant human hyaluronidase (rHuPH20), Paclitaxel, Docetaxel, trastuzumab emtansine, RO7198574, Solution for injection, Concentrate for solution for infusion, Concentrate and solvent for concentrate for solution for infusion, Powder for concentrate for solution for infusion, PHESGO, Kadcycla
Institut Jules Bordet, F. Hoffmann-La-Roche
HER2-positive, estrogen receptor (ER)-negative/progesterone receptor (PR)-negative, node-negative early breast cancer, Early breast cancer, Diseases [C] - Cancer [C04]
 
 
2021-000689-14: Finnish national phase 2 study to evaluate targeted drug treatment in advanced cancer. Yksilöllistä syövänhoitoa selvittävä kansallinen vaiheen 2 lääketutkimus edenneessä syövässä.

Not yet recruiting
2
250
Europe
abemaciclib, pralsetinib, Tablet, Capsule, hard, Injection, Infusion, Capsule, Stivarga, Alecensa, Cotellic, Erivedge, Phesgo, Rozlytrek, Tecentriq, Zelboraf, Verzenios, Retsevmo, Erleada, Tafinlar, Mekinist, Gavreto, Lynparza
Helsinki University Hospital, Helsinki University Hospital
Patients with an advanced solid tumor for which standard treatment options no longer exist and with acceptable performance status and organ function with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test., Patients with advanced cancer where standard treatment options no longer exist. Potilaat, jotka sairastava edennyttä syöpää, johon tavanomaiset hoitolinjat eivät enää tehoa., Diseases [C] - Cancer [C04]
 
 
2021-002323-38: Neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab with or without inavolisib Neoadjuvante endokrine Therapie in Kombination mit Trastuzumab, Pertuzumab mit oder ohne Inavolisib

Not yet recruiting
2
170
Europe
inavolisib (GDC-0077), Phesgo, RO7113755, RO7198574, Film-coated tablet, Solution for injection in vial, Phesgo
German Breast Group, F. Hoffmann-La Roche Ltd
Patients with early breast cancer Patienten mit primärem Brustkrebs, Patients with early breast cancer Patienten mit primärem Brustkrebs, Diseases [C] - Cancer [C04]
 
 
2022-003865-39: Treatment of HER2+ early breast cancer with either trastuzumab-deruxtecan or standard-of-care treatment (chemotherapy + antibodies) Behandlung von frühem, HER2-positiven Brustkrebs mit Trastuzumab-Deruxtecan im Vergleich zu Standardtherapie (Chemotherapie + Antikörper)

Not yet recruiting
2
402
Europe
Trastuzumab-Deruxtecan (T-DXd), Paclitaxel, Docetaxel, Carboplatin, Trastuzumab, Phesgo, Pertuzumab, DS-8201a, Powder for concentrate for solution for infusion, Concentrate for solution for injection/infusion, Solution for injection, Enhertu
Westdeutsche Studiengruppe GmbH, AstraZeneca
HER2+ early breast cancer HER2+ früher Brustkrebs, Breast Cancer Brustkrebs, Diseases [C] - Cancer [C04]
 
 
MyTACTIC, NCT04632992: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed
2
252
US
Entrectinib, Rozlytrek™, RG6268, RO7102122, Inavolisib, GDC-0077, RG6114, RO7113755, Alectinib, Alecensa®, RG7853, RO5424802, Ipatasertib, GDC-0068, RG7440, RO5532961, Atezolizumab, Tecentriq®, RG7446, RO5541267, Trastuzumab Emtansine, Kadcyla®, RG3502, RO5304020, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, PH FDC SC, Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously, RG6264, RO7198574, Tucatinib, Tukysa™, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, RG6058, RO7092284, MTIG7192A, Pralsetinib, GAVRETO™, RG6396, RO7499790
Genentech, Inc.
Advanced Unresectable or Metastatic Solid Malignancy
12/23
02/24
DEMETHER, NCT06172127: PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Not yet recruiting
2
165
NA
Trastuzumab deruxtecan, T-DXd, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, PHESGO, Pertuzumab-Trastuzumab FDC SC, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
MedSIR, Hoffmann-La Roche
HER2-positive Breast Cancer
11/26
05/29
NCT05730712: Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
25
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Enzalutamide, ASP9785, MDV3100, Xtandi, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Questionnaire Administration
Mayo Clinic
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
10/25
10/25
NCT06439693: The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Not yet recruiting
2
72
US
Nab-Paclitaxel, Abraxane, ABI-007, Albumin-bound paclitaxel, Paclitaxel, Taxol, Docetaxel, Taxotere, Phesgo, pertuzumab plus trastuzumab plus hyaluronidase-zzxf, RG6264, RO7198574, T-DM1, ado-trastuzumab emtansine, Kadcyla, Pertuzumab, Trastuzumab Deruxtecan, Enhertu, fam-trastuzumab deruxtecan-nxki, T-DXd, DS-8201a, Trastuzumab Subcutaneous Subcutaneous, Herceptin Hylecta, Trastuzumab and hyaluronidase-oysk, Tucatinib, Trastuzumab
Dana-Farber Cancer Institute, Translational Breast Cancer Research Consortium, Johns Hopkins University
Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
03/30
03/33
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/24
12/25
PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting
2
393
Europe
Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla
MedSIR, Hoffmann-La Roche
Early Breast Cancer
09/25
03/28
CHERRY-PICK, NCT06068985: Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

Not yet recruiting
2
63
RoW
PHESGO
Latin American Cooperative Oncology Group, Roche Pharma AG, Oncoclínicas
Breast Cancer, HER2-positive Breast Cancer
10/26
10/31
ADEPT, NCT04569747: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Recruiting
2
375
US
Pertuzumab+TRASTUZUMAB, PHESGO, ADJUVANT ENDOCRINE THERAPY, Letrozole, Anastrozole, Exemestane, Tamoxifen, Leuprolide, or other LHRH agonist (per investigator discretion)
Dana-Farber Cancer Institute, Genentech, Inc.
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
09/26
09/30
GeparPiPPa, NCT05306041: Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Recruiting
2
170
Europe
Inavolisib, PHESGO, Endocrine therapy
German Breast Group, Roche Pharma AG
HER2-positive Breast Cancer
10/26
01/27
FINPROVE, NCT05159245: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Recruiting
2
250
Europe
Alectinib, Alecensa, Cobimetinib, Cotellic, Vismodegib, Erivedge, Trastuzumab+Pertuzumab, Phesgo, Entrectinib, Rozlytrek, Atezolizumab, Tecentriq, Vemurafenib, Zelboraf, Regorafenib, Stivarga, Apalutamide, Erleada, Abemaciclib, Verzenio, Selpercatinib, Retevmo, Dabrafenib, Tafinlar, Trametinib, Mekinist, Dabrafenib+Trametinib, Tafinlanr+Mekinist, Pralsetinib, Gavreto
Helsinki University Central Hospital
Advanced Cancer, Solid Tumor, Haematological Malignancy
11/26
11/26
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade

Suspended
2
1065
Europe, RoW
Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1
Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie
HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
06/27
03/29
ELPIS, NCT04301375: Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy ( Trial)

Not yet recruiting
2
27
Europe
Pertuzumab and trastuzumab FDC subcutaneous, Paclitaxel, TDM1, Endocrine therapy, Omission surgery
David Garcia Cinca, Fundacion Clinic per a la Recerca Biomédica
Mammary Cancer
07/27
07/27
NCT05020860: Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Recruiting
2
185
US
Paclitaxel, Taxol, Carboplatin, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Pembrolizumab, Keytruda, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, PHESGO
Baylor Breast Care Center
Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
08/27
11/29
COGNITION-GUIDE, NCT05332561: Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer

Recruiting
2
240
Europe
Atezolizumab 1200 mg in 20 ML Injection, Tecentriq, Inavolisib, Ipatasertib, Olaparib, Lynparza, Sacituzumab govitecan, Trodelvy, Trastuzumab/pertuzumab, Phesgo
German Cancer Research Center
Early-stage Breast Cancer
03/30
12/30
IMPRESS-Norway, NCT04817956: Improving Public Cancer Care by Implementing Precision Medicine in Norway

Recruiting
2
3000
Europe
Atezolizumab, Atezolizumab combined with bevacizumab, Phesgo (trastuzumab og pertuzumab), Alectinib, vismodegib, entrectinib, Vemurafenib and cobemitinib, Niraparib, Dostarlimab, Ceritinib
Oslo University Hospital, Haukeland University Hospital, St. Olavs Hospital, University Hospital of North Norway, University Hospital, Akershus, Vestre Viken Hospital Trust, Hospital of Southern Norway Trust, Ostfold Hospital Trust, The Hospital of Vestfold, Helse Stavanger HF, Nordlandssykehuset HF, Sykehuset Innlandet HF, Helse Forde, Helse Fonna HF, Helse Nord-Trøndelag HF, Helse Møre og Romsdal HF, Sykehuset Telemark, Lovisenberg Diakonale Hospital
Cancer Metastatic
03/40
04/45
MORPHEUS BC, NCT04802759: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Recruiting
1/2
510
Europe, US, RoW
Giredestrant, GDC-9545, RO7197597, RG6171, Abemaciclib, Verzenio™, Ipatasertib, GDC-0068, RO5532961, RG7440, Inavolisib, GDC-0077, RO7113755, RG6114, Ribociclib, Kisqali®, Everolimus, Afinitor®, Samuraciclib, ICEC0942, CT7001, PH FDC SC, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, RO7198574, RG6264, Palbociclib, Ibrance®, Atezolizumab, Tecentriq®, RO5541267, RG7446
Hoffmann-La Roche
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
04/26
10/26

Download Options